ADVANCED HCC

TREATMENT STRATEGIES FOR PATIENTS INELIGIBLE FOR IO OR THOSE WITH PROGRESSION ON IO

For patients with HCC who are **ineligible for IO**, the tyrosine kinase inhibitors (**TKIs**) sorafenib and lenvatinib remain the **recommended 1st line treatment options**



After **progression on 1st line IO**, multiple treatment strategies are available. If a **clinical trial** is not available, **switching to a TKI**, or considering **alternative IO-based approaches** may be viable options based on patient eligibility, disease factors, and local availability.



Post-IO progression, two main **TKI-based approaches** are available:



Transition to 2nd line therapy should be considered after **radiologic** or **clinical progression**



HCC, hepatocellular carcinoma; IO, immuno-oncology (therapy); TKI, tyrosine kinase inhibitor. | Key messages summarised from peer-reviewed literature and clinical guidelines. Please refer to the slide deck for full references. | This programme is supported by an Independent Educational Grant from Bayer. This content is intended for healthcare professionals only.

COR2ED

Go to COR2ED.COM for more information and resources

June 2025